Pharmaceutical and biotech companies like Johnson & Johnson, Moderna, and Inovio Pharmaceuticals haveResearch on a coronavirus vaccine has a lot of value for public health, but it won't yield a quick cure
That's what happened in previous coronavirus outbreaks, including SARS in 2002-2003 and MERS in 2012. In those cases, vaccine candidates haven't yet progressed beyond early safety testing in people, though researchers are still working on a MERS shot. "I would be extremely happy to be wrong, but I don't really see how a vaccine can get put together in time to help out with the likely course of this current outbreak," Derek Lowe, author of the industry blogThere have been great improvements over the past few years to create vaccines from scratch more quickly, said Dr. Stanley Plotkin, who has been involved in vaccine research since 1958 and played a big role in developing the rubella vaccine in the 1960s.
US health officials have put forward a speedy timeline, but it represents just the first steps of drug development., director of the National Institutes of Health's infectious disease unit, said Friday the agency plans to start testing Moderna's potential vaccine in people within the next next two and a half months, barring any setbacks.
That tees up late-stage testing, the most challenging stage of drug development. Mayo Clinic's Poland said it typically requires tens of thousands of patients and hundreds of millions of dollars to run the final phase of testing to make sure a vaccine works and monitor its side effects. From here, the outbreak can go in two directions, Poland said. It could dwindle out like SARS did or evolve into a full-blown pandemic. When thinking back to the previous SARS, MERS and Zika outbreaks, the world's responses have repeatedly fallen victim to a short attention span.
Long way to go ...
if France could collect EUR 1bn to rebuild NotreDame an equal sum of money would be well invested in a vaccine 2019nCoV
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
La source: BusinessInsider - 🏆 729. / 51 Lire la suite »
La source: BusinessInsider - 🏆 729. / 51 Lire la suite »